| 133 Plasmodium falciparum full life cycle and Plasmodium ovale liver stages in humanized mice.
132 A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.
131 A novel multiple-stage antimalarial agent that inhibits protein synthesis.
130 A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primates.
129 The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs.
128 A forward genetic screen identifies erythrocyte CD55 as essential for Plasmodium falciparum invasion.
127 Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.
126 RIFINs are adhesins implicated in severe Plasmodium falciparum malaria.
125 Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate.
124 The in vivo dynamics of antigenic variation in Trypanosoma brucei.